Alzheimer's drug, Eli Lilly's donanemab, can slow disease by a few months, with risks, study finds

Eli Lilly's experimental Alzheimer's drug donanemab​ can modestly slow the worsening of the disease by about four to seven months, according to researchers.

Related Keywords

Japan ,California ,United States ,Amsterdam ,Noord Holland ,Netherlands ,San Francisco ,Japanese ,Americans ,American ,Eli Lilly ,Gild Rabinovici ,John Sims ,Eric Widera ,Journal Of The American Medical Association ,University Of California ,Drug Administration ,Alzheimer Association International Conference ,American Medical Association ,Association International Conference ,Renaud La Joie ,Food And Drug Administration ,Alzheimer Amp 039s Disease ,Fda ,